Idecabtagene Vicleucel
bms
['mmsm']
real-life ide-cel data at #asco2022 n=159, but 12 died before cell delivery not included in denominator ( intent to treat response rate!) pfs=8.9 months, similar to trial data prior bcma therapy associated with lower response rates, think before using belantamab! #mmsm 
Cancer doctor at @huntsmancancer with interest in myeloma, supportive care, end of life, cost-effective/evidence-based care and med-ed. No COI. Views own.